Ubs Group Ag Aim Immuno Tech Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Ubs Group Ag holds 21,322 shares of AIM stock, worth $5,330. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,322

Previous 21 101433.33%

Holding current value

$5,330

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.35 - $0.61 $7,455 - $12,993	21,301 Added 101433.33%	21,322 $7,000
Q1 2024 May 13, 2024	SELL	$0.33 - $0.48 $4,240 - $6,168	-12,850 Reduced 99.84%	21 $0
Q4 2023 Feb 09, 2024	SELL	$0.4 - $0.56 $1,452 - $2,032	-3,630 Reduced 22.0%	12,871 $5,000
Q3 2023 Nov 09, 2023	BUY	$0.44 - $0.71 $7,254 - $11,706	16,488 Added 126830.77%	16,501 $7,000
Q1 2023 May 12, 2023	SELL	$0.32 - $0.77 $9,363 - $22,531	-29,262 Reduced 99.96%	13 $0
Q4 2022 Feb 08, 2023	BUY	$0.31 - $0.6 $7,192 - $13,921	23,202 Added 382.05%	29,275 $9,000
Q3 2022 Nov 10, 2022	BUY	$0.57 - $0.81 $416 - $592	731 Added 13.68%	6,073 $4,000
Q2 2022 Aug 10, 2022	BUY	$0.78 - $1.27 $4,162 - $6,776	5,336 Added 88933.33%	5,342 $4,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.18 $2 - $4	-4 Reduced 40.0%	6 $0
Q3 2021 Nov 15, 2021	SELL	$1.91 - $2.17 $13 - $15	-7 Reduced 41.18%	10 $0
Q1 2020 May 01, 2020	SELL	$0.56 - $6.1 $4 - $48	-8 Reduced 32.0%	17 $0
Q4 2019 Feb 14, 2020	BUY	$0.39 - $0.71 $1 - $3	5 Added 25.0%	25 $0
Q3 2019 Nov 14, 2019	BUY	$0.71 - $4.42 $14 - $88	20 New	20 $0

Others Institutions Holding AIM

# of Institutions

Shares Held

8.44M

Call Options Held

Put Options Held

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $12M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account